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ABSTRACT
The magnetic properties and safety of dextran-coated superparamagnetic iron oxide nanoparticles (SPIONs) have facilitated their clinical use as MRI contrast agents and stimulated research on applications for SPIONs in particle imaging and magnetic hyperthermia. The wider clinical potential of SPIONs, however, has been limited by their rapid removal from circulation via the reticuloendothelial system (RES). We explored the possibility of extending SPIONs circulatory time using fucoidan, a seaweed-derived food supplement, to inhibit RES uptake.
The effects of fucoidan on SPION biodistribution were evaluated using ferucarbotran, which in its pharmaceutical formulation (Resovist®) targets the RES. Ferucarbotran was radiolabeled at the iron oxide core with technetium-99m ( 99m Tc; t1/2 = 6 hours) or zirconium-89 ( 89 Zr; t1/2 =
days). Results obtained with 99m
Tc-ferucarbotran demonstrated that administration of fucoidan led to a 4-fold increase in the circulatory half-life (t1/2 slow) from 37.4 to 150 minutes (n = 4; P < 0.0001). To investigate whether a longer circulatory half-life could lead to concomitant increased tumor uptake, the effects of fucoidan were tested with 89 Zrferucarbotran in mice bearing syngeneic subcutaneous (GL261) tumors. In this model, the longer circulatory half-life achieved with fucoidan was associated with a doubling in tumor SPION uptake (n = 5; P < 0.001). Fucoidan was also effective in significantly increasing the circulatory half-life of perimag®-COOH, a commercially available SPION with a larger hydrodynamic size (130 nm) than ferucarbotran (65 nm). These findings indicate successful diversion of SPIONs away from the hepatic RES and show realistic potential for future clinical applications.
Table of content graphic:
Dextran-coated superparamagnetic iron oxide nanoparticles (SPIONs) have many applications in biomedical research and a proven safety track record in clinical practice as contrast agents for magnetic resonance imaging (MRI) and as treatments for anemia. [1] [2] [3] [4] Moreover, recent advances in magnetic hyperthermia therapy 5 and imaging techniques such as magnetic particle imaging (MPI) 6 and photoacoustic imaging 7 have resulted in an increased interest for SPIONbased contrast agents. However, SPIONs show preferential uptake by in situ macrophages within the reticuloendothelial system (RES) of the liver and spleen. Therefore, use of SPIONs in the clinic to date has mainly been to detect malignant lesions within these tissues 8 or to image macrophage density in diseases such as atherosclerosis [8] [9] [10] [11] and type 1 diabetes. 12 The sequestration of SPIONs by the RES leads to very short circulation time and limits the wider imaging and therapeutic potential of SPIONs for non-RES targeted applications, such as tumor targeting through enhanced permeability and retention (EPR). 13 Various methods to increase the half-life of SPIONs have been explored, many utilizing coatings (such as high density polyethylene glycol (PEG) polymers), [14] [15] [16] [17] designed to sterically prevent hydrophobic and electrostatic interactions with components of the blood. [14] [15] [16] [17] [18] The brush-like structures of the coat help to generate repulsive steric forces, 19 reduce the formation of a protein corona 20 and thus protect nanoparticles from recognition by macrophages. 21 Newer SPION modification technologies include bio-nano hybrid systems with biomimetic coatings, coating with 'self' peptides, or encapsulation within cell membranes. [22] [23] [24] [25] [26] [27] [28] An alternative strategy to prolong SPIONs circulatory time is to pre-treat with agents that inhibit the innate immune system components responsible for the rapid clearance of nanoparticles, thereby imposing a temporary block on circulatory removal and potentially allowing greater access of SPIONs to other tissues. This 'blocking approach' has the advantage that there is no requirement for complex chemical modification of SPIONs and it can be readily applicable to SPIONs already approved for clinical use. A number of agents have been investigated as potential blockers to facilitate SPIONs accessibility, e.g. clodronate liposomes to deplete macrophages, gadolinium chloride (GdCl3) to inhibit Kupffer cell phagocytosis, complement inhibitors and the use of decoy nanoparticles to saturate macrophages prior to the injection of the therapeutic nanoparticles. 29 Whilst there is some evidence of promise, none have yet been taken forward to the clinic and potential toxicity is a concern. For instance, dextran sulfate 500 (DSO4 500) can be used to block macrophage uptake of ferucarbotran, the SPION component of Resovist®, 30 a clinical T2 MRI contrast agent designed to target the RES in order to detect focal liver cancerous lesions. 31 However, DSO4 500 is not suitable for clinical development due to its toxic side effects (e.g. reversible thrombocytopenia and alopecia).
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In the search for a clinically translatable alternative we turned our attention to fucoidans, a class of naturally occurring sulfated polysaccharides which are known ligands of the scavenger receptor class A (SR A). 33 SR A are responsible for macrophage uptake of dextran-coated SPIONs. [34] [35] [36] [37] [38] Fucoidans are composed mainly of fucose and sulfate ester groups and can be extracted from different species of brown seaweed (e.g. Fucus vesiculosus, Undaria pinnatifida and Macrocystis pyrifera) and marine invertebrates (e.g. sea urchins and sea cucumbers). 39, 40 Seaweed is eaten in many cultures and seaweed extracts are readily available in many over the counter food supplements. 41 The safety profile of fucoidans makes them promising agents for clinical development and in recent years they have been subjected to intense research due to their versatile biological applications. 39, 40, 42 Fucoidans are reported to possess antioxidant, antiviral, anticoagulant and anti-inflammatory properties, and to modulate blood lipid levels. 39, 40 Fucoidan has also been studied as an anticancer agent 43 and has been investigated in osteoarthritis, stem cell modulation, kidney disease and liver disease. 41 In this study, we use radiolabeled SPIONs and in vivo preclinical nuclear imaging to investigate the biodistribution of dextran-coated SPIONs. We apply these methods to evaluate the potential of fucoidans to increase the circulatory presence of SPIONs and enhance tumor uptake.
RESULTS AND DISCUSSION

In vitro internalization and inhibition of ferucarbotran uptake by macrophages
The uptake of ferucarbotran was first evaluated in vitro using the murine monocyte/macrophage cell line RAW 264.7 44 that has been extensively employed in the study of the interactions of nanoparticles, specifically SPIONs, with macrophages. [35] [36] [37] 45 Ferucarbotran uptake by the cells was measured quantitatively by the ferrozine iron assay 46 and visualized using Prussian blue (Perls') staining. [47] [48] [49] [50] [51] Internalization of electron-dense SPIONs by cells was confirmed by transmission electron microscopy (TEM). The results, shown in Figure 1A , revealed that macrophage iron uptake increased in a dose dependent manner in proportion to the concentration of ferucarbotran incubated with the cells. This is consistent with the endocytosis of SPIONs by macrophages observed by others 36, 52 and thought to be mainly mediated via SR A [34] [35] [36] [37] [38] and clathrin-mediated endocytosis. 35, 36 Studies investigating the role of other carbohydrate recognition pathways in SPION uptake indicate that, whilst mannose receptors (CD206) and SIGNR1 can mediate the uptake of bacterial polysaccharides such as dextrans, these receptors do not appear to be involved in the uptake of dextran coated SPIONs. 37 Perls' staining is a long-established method to stain SPIONs in cells and tissues giving dense blue aggregates. Thus, the presence of blue aggregates within RAW 264.7 cells incubated with ferucarbotran ( Figure 1B ) was taken to demonstrate the presence of SPIONs. TEM was used to show the internalization of ferucarbotran, which appears within the cells as aggregates rather than as single particles ( Figure 1C ). All intracellular nanoparticles detected were in cytoplasmic vesicles and none were visualized within the nucleus. Low magnification TEM images of macrophages showed invagination of the cell membrane ( Figure 1D ), indicating nanoparticle aggregates in the process of being endocytosed; non-internalized nanoparticles were visualized on the cell surface membrane. To test if the electron dense aggregates were SPIONs, energy dispersive X-ray (EDAX) microanalysis of unstained TEM slides was performed ( Figure 1E -F). The presence of elemental iron indicated that the aggregates were indeed SPIONs, as opposed to other electron dense structures found within cells.
Fucoidans from 3 different species of seaweed: Fucus vesiculosus (FVF), Macrocystis pyrifera
(MPF) and Undaria pinnatifida (UPF) were evaluated, in comparison with DSO4 500, for ability to reduce uptake of ferucarbotran by RAW 264.7 macrophages. Cells were pretreated with the fucoidans or DSO4 500 at concentrations of 30 and 60 g/mL, followed by incubation with ferucarbotran at 0.1, 0.5 and 1 mgFe/mL. Results (Figure 1G ), demonstrated that pretreatment with fucoidans led to a significant reduction in the uptake of ferucarbotran at all tested conditions. These results support published literature on the in vitro blocking effect of both DSO4 500 53 and fucoidan 54 on nanoparticle uptake by macrophages. 
In vivo effect of fucoidan on the circulation time and biodistribution of ferucarbotran
Preliminary in vivo experiments were conducted using NIR-labeled ferucarbotran, a method previously established as suitable to measure blood concentrations of this nanoparticle. 30 These experiments confirmed that all three fucoidans were capable of significantly increasing the blood levels of ferucarbotran, demonstrable at one hour following particle injection. Table S5 ). 55, 56 This method has been successfully used in several studies to evaluate the biodistribution of SPIONs in vivo and shows negligible leakage of 99m
Tc-DPA-ale in vivo (Supplementary Figure S2) . [55] [56] [57] [58] [59] Labeling SPIONs using radionuclides has significant advantages over other imaging strategies (e.g. MRI or optical imaging) as it allows accurate quantitative information of their biodistribution at the wholebody level. The results showed a significant change in the pharmacokinetic behavior of ferucarbotran in the FVF-treated mice when compared to the controls ( Figure 3A ). The circulation half-life (t1/2) and the area under the curve (AUC), calculated using a two-compartment pharmacokinetic model from the blood sampling results, revealed that FVF increased the t1/2 (slow) 4-fold, from 37.4 to 150 minutes (n = 4; P < 0.0001). In addition, the AUC, representative of the total exposure of the animals to systemically circulating SPIONs, increased 3.5-fold, from 1615 ± 93 %ID⋅min/g to 5699 ± 138 %ID⋅min/g (n = 4; P < 0.0001). Tc-ferucarbotran was visualized mainly within the liver for FVF (-) mice, whereas in FVF (+) mice, a blood pool presence was still observed, with only minor uptake in the liver. These findings support the hypothesis that FVF is able to block the uptake of ratios demonstrated significant differences in the uptake within the liver, with a liver to blood ratio of 8.3 ± 2.8 compared to only 0.5 ± 0.1 in the FVF (+) counterpart (n = 5; P < 0.01).
However, there was no significant difference in tissue to blood ratios for spleen, indicating that the increased %ID/g value for this organ was due to the higher blood levels. All other tissues showed similar tissue to blood ratios in the FVF (+) vs. FVF (-) groups. After radioactive decay, sections of the excised livers were stained using Prussian blue to determine whether the reduced liver uptake of SPIONs in the FVF treated mice could be visualized histologically. The resulting images indicated that staining appeared to be lower and less intense in the livers of mice pretreated with FVF (Supplementary Figure S3A) . Digital image analysis, performed to obtain a less subjective measurement, supported the observation that Perls' stain uptake in FVF treated mice (n = 2) was reduced overall and less intense than in the control mice (n = 2) (Supplementary Figure S3B) . These results further support the hypothesis that FVF blocks the uptake of dextran-coated SPIONs, such as ferucarbotran, within the liver, although the mechanism by which SPION uptake is inhibited remains unclear. As ligands of SR A, 33 fucoidans could simply compete with and inhibit SR A uptake of dextran-coated SPIONs by macrophages. However, other receptors and immune recognition pathways may also be involved, leading to complex uptake mechanisms. Furthermore, SPIONs are known to develop a 'corona' of proteins when exposed to biological milieu, which can influence both their biocompatibility and biological fate. 60, 61 There is evidence that the presence of complement Supplementary Tables S8 and S9 .
Evaluating the effect of FVF blocking on the accumulation of SPIONs in tumors
In order to track ferucarbotran for longer time periods, the iron-oxide cores of the SPIONs were directly radiolabeled with the positron-emitter zirconium-89 ( 89 Zr; t1/2 = 3.3 days), using a recently described method shown schematically in Figure 4 . 65 This method caused an increase in the hydrodynamic diameter of ferucarbotran following labeling (z-average: 53.6 ± 0.1 to 127 ± 14 nm) as determined by dynamic light scattering (DLS) (Supplementary Table S6 ). Despite this increase in hydrodynamic size, 89 Zr-ferucarbotran remained in dispersion with no evidence of precipitation. This increase in size could result in more rapid circulatory clearance as larger SPIONs are known to possess shorter half-lives 66 and we predicted it could be more challenging to maintain 89 Zr-ferucarbotran in circulation, compared with 99m Tc-ferucarbotran.
To evaluate whether FVF could meet this challenge and also lead to a concomitant increase in accumulation of SPIONs within tumors, the subcutaneous GL261 syngeneic C57BL/6 mouse model was utilized. 67 GL261 has been extensively used to assess the efficacy of anti-cancer therapies including immunotherapies for the treatment of gliomas. 68, 69 Another advantage of utilizing C57BL/6 mice was to test whether FVF is also active in strains of mice other than Balb/c. Results showed that, consistent with the observed increase in hydrodynamic size, the circulatory clearance of 89 Zr-ferucarbotran occurred faster than that previously observed for Zr-ferucarbotran in select post-mortem harvested organs at 24 h post injection. Inset shows the tumor uptake. *** P  0.001, ** P < 0.01 and * P < 0.05 compared to FVF (-) as measured using an unpaired two-tailed t-test. Bars represent mean values and error bars are for the standard error of the mean (SEM). Full organ data can be seen in Supplementary Tables S10 and S11.
Testing the effects of fucoidan on the uptake of perimag® SPIONs in vitro
To determine whether the blocking effects of fucoidan were applicable to other SPIONs, FVF was tested on perimag® (Table 1) , a family of SPIONs with favorable properties for magnetic resonance and magnetic particle imaging, stem cell tracking, and hyperthermia therapy. [80] [81] There are a number of differences between perimag® SPIONs and ferucarbotran; ferucarbotran is coated with carboxydextran and has a hydrodynamic diameter of approximately 65 nm, whilst perimag®-COOH is significantly larger (130 nm) and has a plain dextran coating (perimag®-plain) subsequently functionalized with carboxylic acid groups. Thus, perimag® can be controlled in terms of the quantity of surface carboxylic acid groups, providing a versatile basis for SPION development. Perimag®-plain can also be functionalized with positively charged amine groups (perimag®-NH2). 
* Measured in 5 mM NaCl on a Zetasizer Nano ZS90 (Malvern, Worcestershire, UK)
First, the interaction of perimag® SPIONs with RAW 264.7 macrophages was investigated and the effects of fucoidan on this interaction evaluated. The results ( Figure 6 ) revealed that all perimag® SPIONs had lower macrophage uptake than ferucarbotran, with only perimag®-COOH showing strong uptake. Cellular uptake of the near-neutral perimag®-plain and the positively charged perimag®-NH2 was low, irrespective of whether fucoidan or DSO4 500
were present. These in vitro findings are consistent with the predisposition of macrophages to take up negatively charged particles. 82 The relatively lower macrophage uptake of perimag®-COOH compared to ferucarbotran could be attributable to the differences in their charge or hydrodynamic diameters as previously observed with other particles. 
Testing the effect of FVF on the biodistribution of perimag®-COOH
Perimag®-COOH was radiolabeled with 89 Zr as described for ferucarbotran ( Figure 4 ). The perimag® SPIONs showed superior labelling stability as, in contrast to 89 Zr-ferucarbotran, 89 Zr-perimag®-COOH did not show any significant change in size when analyzed by DLS (Supplementary Table S7) . 89 Zr-perimag®-COOH was injected i.v. into C57BL/6 mice either alone (FVF (-), with a preceding injection of fucoidan (FVF (+) pre-injection) or in Tc-ferucarbotran resulting in faster clearance by the RES.
Nonetheless, PET imaging appeared to show a lower signal in the liver of mice treated with FVF compared to the FVF (-) controls. Tissue to blood ratios at 80 minutes showed a lower ratio in the liver for mice treated with FVF, although these differences were not found to be statistically significant. In summary, FVF successfully increased the circulatory half-life of perimag®-COOH confirming that this finding was not limited to ferucarbotran. Full organ count data is available in Supplementary Tables S12, S13, S14 and S15.
CONCLUSIONS
Rapid circulatory clearance is considered one of the major limitations in the development of nanoparticles. We report a perspective to prolong the half-life of one class of nanoparticle, dextran-coated SPIONs, without the need to change their physicochemical characteristics.
In summary, we used two different radiolabeling strategies ( Fucoidan is readily available as a natural food supplement with no reported toxic side effects either in vitro or in vivo. 43 There are ongoing discussions regarding the effectiveness of nanoparticle delivery, with concern that over the last decade the average delivery of systemically administered particles to tissues of interest has remained below 1% of the administered dose, despite the utility of both passive and active targeting. 85, 86 Sequestration of particles by the RES is a major factor in this low delivery and by prolonging the circulation time, fucoidan could work synergistically with passive and active targeting technologies, providing a generic means to improve the delivery of many different nanoparticles.
Removal of nanoparticles by the RES leads to a lack of efficacy because the particles are sequestered away from the intended sites of delivery and into the liver and spleen. 22, 87 Approaches for RES avoidance have long been sought and is most commonly tackled by modifying SPIONs coatings with hydrophilic polymer coatings (e.g. PEG, PVP, poloxamines and poloxamers) to prolong circulation times. 88 However, modifying the surface coatings in this way changes the physical properties of the nanomaterial and is therefore unsuitable when using clinical products with well-studied safety profiles. By overcoming the rapid RES clearance of SPIONs, the work presented in this paper could provide a step towards the clinical development of nanomedicines.
EXPERIMENTAL SECTION
Materials.
Ferucarbotran was purchased from Meito Sangyo Co. LTD., Tokyo, Japan.
Perimag® was obtained from Micromod Partikeltechnologie GmbH. All other materials were purchased from Sigma Aldrich (Dorset, UK) unless otherwise specified. On the following day, the cells were treated with ferucarbotran at three different concentrations (0.1, 0.5, 1 mgFe/mL) for 4 hours at 37°C. Cells were then washed 3 times with cold PBS to remove excess unbound SPIONs. Next, the cells were lysed with 200 L of 50 mM sodium hydroxide (NaOH) and the intracellular iron content was determined using the colorimetric ferrozine assay 46 and then compared to a standard curve of ferucarbotran samples of known Ultrathin sections were cut using a diamond knife (Diatome) and collected on 300HS, 3.05 mm copper grids (Gilder). The ultrathin sections were stained using saturated alcoholic uranyl acetate (UA) (TAAB) for 5 minutes followed by Reynold's lead citrate, also for 5 minutes.
Cell uptake experiments. All in vitro experiments
Sections examined with EDAX were not stained with UA or lead. The sections were viewed and photographed using a Philips CM120 transmission electron microscope fitted with EDAX DX-4 microanalytical system for X-ray microanalysis of the samples.
Cell blocking experiments. Cells were pre-treated with the fucoidans or DSO4 500 at either 30 or 60 g/mL for 15 minutes before being challenged with ferucarbotran (0.1, 0.5, 1 mgFe/mL) for 4 hours at 37°C. All experiments were performed in triplicate and repeated on three separate occasions on different days. For blocking experiments with FVF and DSO4 500 at equimolar concentrations, cells were pretreated with 0.17 M of either blocker before adding 0.5 mgFe/mL of the SPIONs (ferucarbotran, perimag®-plain, perimag®-COOH or perimag®-NH2) for 4 hours. Then cells were lysed and the intracellular iron content determined using ferrozine assay as described above.
In vivo experiments. All in vivo experiments were performed using mouse models in was then added and the pH raised to 8 using 1M Na2CO3 (aq.). This step was performed cautiously as acid neutralization with Na2CO3 generates CO2 gas and base must be added carefully to avoid loss of radioactivity. Chelex-treated water was again added (200 µL),
followed by the addition of ferucarbotran (52 µL, 58 mgFe/mL). The mixture was then vortexed briefly and then incubated at 100 °C for 1 h. The reaction was allowed to cool to room temperature and DTPA (50 µL, 10 mM (pH 7.5) was added and left to stir at room temperature for 30 minutes. After which time, the nanoparticle mixture was purified using size exclusion chromatography (SEC) (PD-10 Sephadex, G25) and eluted with fractions of sterile saline (recovery = 78%). 89 Zr-ferucarbotran was diluted to 260 μL using sterile saline. The conjugate was then characterized using dynamic light scattering (DLS) (Supplementary Table S6 ). µL) was then added and the pH raised to 8 using 1M Na2CO3 (aq.); base was added carefully to avoid loss of radioactivity. Chelex-treated water was again added (170 µL), followed by the addition of perimag®-COOH (20 µL, 18.2 mgFe/mL). The mixture was then vortexed briefly and incubated at 100 °C for 60 minutes. The reaction was allowed to cool to room temperature and DTPA (50 µL, 10 mM (pH 7.5)) was added and left to stir at room temperature for 30 minutes. After which time, the nanoparticle mixture was purified using size exclusion chromatography (SEC) (PD10 Sephadex, G25) and eluted with fractions of sterile saline (recovery = 81%). 89 Zr-Perimag®-COOH was diluted to 260 μL using sterile saline. The conjugate was then characterized using DLS (Supplementary Table S6 ).
Radiolabeling of perimag®-COOH
PET/CT imaging. C57BL/6 mice were injected with 100 μL 89 Zr-ferucarbotran or 89 Zrperimag®-COOH solution (1.76 mgFe/kg), preceded by, or at the same time as, 100 μL of PBS or FVF (15 mg/kg, in PBS). At pre-set time points following injection of SPIONs, mice were anaesthetized with isoflurane (2% in oxygen) and placed on the preheated bed of the scanner (set at 38 C). Whole body static PET scans were acquired using nanoScan PET/CT (Mediso, Budapest, Hungary) followed by CT image acquisition. PET images were acquired using 1-5 coincidence mode and recorded for 20 minutes. CT images were acquired using a 50 kV peak X-ray source and 300 ms exposure time in 720 projections with an acquisition time of 7 minutes. Respiration rate was monitored throughout the scan. PET images were reconstructed using Tera-TomoTM 3D PET reconstruction software (Mediso version 2.01). CT images were reconstructed in voxel size of 68 x 68 x 68 mm using Nucline software (Mediso version 2.01).
Image analysis and three-dimensional (3D) visualization were performed using VivoQuant 
